The stock of Atyr Pharma Inc (NASDAQ:LIFE) registered an increase of 10.98% in short interest. LIFE’s total short interest was 1.15M shares in January as published by FINRA. Its up 10.98% from 1.04 million shares, reported previously. With 894,700 shares average volume, it will take short sellers 1 days to cover their LIFE’s short positions. The short interest to Atyr Pharma Inc’s float is 6.09%.
The stock decreased 1.58% or $0.0086 during the last trading session, reaching $0.5344. About 52,969 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has declined 85.23% since January 23, 2018 and is downtrending. It has underperformed by 85.23% the S&P500.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $16.05 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.
aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage
Among 2 analysts covering aTyr Pharma (NASDAQ:LIFE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. aTyr Pharma had 2 analyst reports since August 15, 2018 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, August 17 by Citigroup. As per Wednesday, August 15, the company rating was maintained by BMO Capital Markets.
More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Globenewswire.com which released: “aTyr Pharma Announces Participation at Upcoming San Francisco Investor Events – GlobeNewswire” on January 02, 2019, also Nasdaq.com with their article: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – Nasdaq” published on January 23, 2019, Nasdaq.com published: “Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca’s, and Cytosorbents â€” What Drives Growth in Today’s Competitive Landscape – Nasdaq” on January 23, 2019. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: Nasdaq.com and their article: “Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon – Nasdaq” published on January 17, 2019 as well as Nasdaq.com‘s news article titled: “How to Turn A 6.9% Yield into a 16% Annual Dividend – Nasdaq” with publication date: January 23, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.